Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 108Lymphoma, Large B-Cell, Diffuse 97Lymphoma 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Lymphoma, Non-Hodgkin 37Lymphoma, Follicular 37Burkitt Lymphoma 36Leukemia 30Multiple Myeloma 29Lymphoma, Mantle-Cell 26Hodgkin Disease 25Lymphoma, T-Cell, Peripheral 20Lymphoma, Large-Cell, Immunoblastic 15Lymphoma, Large-Cell, Anaplastic 15Lymphoma, B-Cell, Marginal Zone 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Neoplasm Metastasis 13Lymphoma, B-Cell 13Leukemia, Lymphocytic, Chronic, B-Cell 12Recurrence 11Neoplasms, Plasma Cell 11Immunoblastic Lymphadenopathy 11Lymphoma, T-Cell 8Dendritic Cell Sarcoma, Interdigitating 8Blast Crisis 8Neoplasms 7Enteropathy-Associated T-Cell Lymphoma 7Waldenstrom Macroglobulinemia 5Primary Myelofibrosis 5Myasthenia Gravis 5

Interventions

Cisplatin 7Etoposide 6Amifostine 6Radiotherapy 5Drug Therapy 5Cyclophosphamide 5apatinib 4Methotrexate 4Filgrastim 4Cytarabine 4sodium thiosulfate 3Methylprednisolone 3Carboplatin 3pegfilgrastim 2glucarpidase 2etoposide phosphate 2Voriconazole 2Vincristine 2Social Determinants of Health 2Pyridoxine 2Nivolumab 2Gemcitabine 2Doxorubicin 2Docetaxel 2Chemotherapy, Adjuvant 2Capecitabine 2trastuzumab deruxtecan 1selinexor 1sargramostim 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Drug-Related Side Effects and Adverse Reactions × Prednisone × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡